@misc{indiciaea38851fbcada,
  title = {Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.},
  author = {Xiuning Le and Antonio Passaro and Yuanyuan Zhao and Yan Huang and Janessa Laskin and Delvys Rodriguez-Abreu and Antonio Calles and Lyudmila Bazhenova and Giuseppe Lo Russo and Natasha B Leighl and Federico Cappuzzo and Nicolas Girard and Sanjay Popat and Wenfeng Fang and Yongzhong Luo and Wenting Li and Zhiyong He and Hui Zhao and Mingjun Li and Qibin Song and Hongyun Zhao and Haidar El Darsa and Isabelle Monnet and Manuel Cobo Dols and Rosario Garc\&\#xed;a Campelo and Robert Jotte and David Berz and Alexander Spira and Maurice P\&\#xe9;rol and Misako Nagasaka and Howard West and Lori Styles and Jianling Li and Fong Clow and Jonathan Goldman and Li Zhang},
  year = {2026},
  doi = {10.1016/s1470-2045(26)00282-2},
  url = {https://pubmed.ncbi.nlm.nih.gov/42636833/},
  note = {Source identifier: 42636833}
}